Screener
Xenon Pharmaceuticals XENE Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0-100% | $0— | $0— | $0— | ||
| $99.22M+32.3% | $88.51M+44.6% | $87.7M+47.5% | $77.05M+35.3% | $74.99M+50.9% | ||
| $23.93M+24.4% | $23.82M+25.1% | $22.07M+22.6% | $19.28M+15.4% | $19.24M-0.8% | ||
| $123.16M+30.7% | $112.33M+40.0% | $109.77M+41.7% | $96.34M+30.8% | $94.23M+36.4% | ||
| -$123.16M-30.7% | -$112.33M-54.4% | -$109.77M-41.7% | -$96.34M-30.8% | -$94.23M-36.4% | ||
| $11.83M+33.0% | $7.46M-8.2% | $5.04M-36.5% | $6.12M-42.1% | $8.9M-18.0% | ||
| -$111.32M-30.5% | -$104.87M-62.3% | -$104.72M-50.6% | -$90.22M-43.0% | -$85.33M-46.5% | ||
| -$585K+6.5% | -$2.57M-702% | $538K+114% | $677K+312% | -$626K-88.0% | ||
| -$110.74M-30.7% | -$102.3M-57.3% | -$105.26M-60.3% | -$90.9M-44.8% | -$84.71M-46.2% | ||
| -$1.11-3.7% | -$1.17-41.0% | -$1.31-56.0% | -$1.15-42.0% | -$1.07-42.7% | ||
| -$122.6M-31.0% | -$111.74M-55.0% | -$109.16M-42.1% | -$95.7M-31.1% | -$93.6M-36.7% | ||
| -$123.16M-30.7% | -$112.33M-54.4% | -$109.77M-41.7% | -$96.34M-30.8% | -$94.23M-36.4% |
FAQ
- Is Xenon Pharmaceuticals profitable?
- Xenon Pharmaceuticals is not currently profitable: it reported a net loss of $409.2M over the trailing twelve months, a -4612.1% net margin.
- What is Xenon Pharmaceuticals's earnings per share?
- Xenon Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.74.
- Where does Xenon Pharmaceuticals's income statement data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.